RestorGenex Corp  

(Public, OTCMKTS:RESX)   Watch this stock  
Find more results for B. Blech
+0.03 (1.28%)
Delayed:   9:40AM EDT
OTCMKTS data delayed by 15 mins - Disclaimer
Currency in USD
Range 2.37 - 2.37
52 week 2.34 - 4.50
Open 2.37
Vol / Avg. 1,500.00/2,522.00
Mkt cap 44.12M
P/E     -
Div/yield     -
EPS -1.01
Shares 18.61M
Beta 0.53
Inst. own 0%
May 11, 2015
Q1 2015 RestorGenex Corp Earnings Release
Apr 6, 2015
Full Year 2014 RestorGenex Corp Earnings Release
Mar 20, 2015
RestorGenex Corp at Biocentury Future Leaders in the Biotech Industry
Mar 10, 2015
RestorGenex Corp at ROTH Conference

Key stats and ratios

Q4 (Dec '14) 2014
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets -43.56% -46.96%
Return on average equity -50.21% -64.33%
Employees 8 -
CDP Score - -


2150 E Lake Cook Rd Ste 750
BUFFALO GROVE, IL 60089-8227
United States - Map
+1-805-2291829 (Phone)
+1-213-9956337 (Fax)

Website links


RestorGenex Corporation. is a specialty biopharmaceutical company initially focused on developing products for dermatology, ophthalmology and women’s health. The Company’s proposed product portfolio includes a cosmeceutical product line. The Company is engaged in product development for both the cosmeceutical market, as well as the prescription dermatology market. The Company’s HYG-102, a soft estrogen, for the treatment of aging skin fragility/thinning; HYG-440, a soft anti-androgen, for the treatment of androgen excess, e.g. acne, male-pattern baldness; P529, for the treatment of keloid scarring, psoriasis, atopic dermatitis, rosacea, actinic keratosis, Dupuytren’s disease and the bullous blistering diseases; HYG-102, is for vulvar and vaginal atrophy (VVA); HYG-102 and HYG-440 target hormonal aging in women which radically affects the mucous membranes.

Officers and directors

Sol J. Barer Ph.D. Chairman of the Board
Age: 68
Stephen M. Simes Chief Executive Officer, Director
Age: 63
Isaac Blech Vice Chairman of the Board
Age: 65
Phillip B. Donenberg Chief Financial Officer, Secretary
Age: 54
Mark Weinberg M.D. Senior Vice President - Clinical Development
David Sherris M.D., Ph.D. Chief Scientific Officer, President - Paloma/VasculoMedics Divisions, Director
Age: 61
Rex Bright Director
Age: 74
Nelson K. Stacks Director
Age: 44